Gabrielle Agin-Liebes

Gabrielle Agin-Liebes is a clinical researcher specialising in psychedelic-assisted therapies, with a primary focus on psilocybin clinical trials and follow-up research in populations with life-threatening cancer and comorbid psychiatric distress. She has been a co‑author on multiple influential studies reporting acute and sustained reductions in anxiety, depression, loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy, and contributed to long‑term follow‑up work that characterises durability of therapeutic effects. Her work sits at the intersection of clinical trial conduct, outcome assessment for existential and psychiatric suffering, and translation of psychedelic protocols into clinical practice.

In addition to trial-oriented publications, Agin-Liebes has contributed to the broader evidence base through survey and methodological work (including studies of clinicians' attitudes toward psychedelic therapies), citizen‑science investigations of microdosing, and preliminary community‑based research on other plant‑medicine models (e.g., ayahuasca). Her research portfolio indicates sustained engagement with both empirical clinical outcomes and the contextual, ethical and implementation questions necessary for integrating psychedelic therapies into mainstream psychiatric and substance‑use treatment pathways.